Trademark: 90191359
Word
BROMAC
Status
Registered
Status Code
700
Status Date
Tuesday, January 18, 2022
Serial Number
90191359
Registration Number
6617801
Registration Date
Tuesday, January 18, 2022
Mark Type
4000
Filing Date
Friday, September 18, 2020
Published for Opposition
Tuesday, November 2, 2021

Trademark Owner History
Mucpharm Pty Ltd - Original Registrant

Classifications
5 Anti-bacterial pharmaceuticals; anti-cancer drugs; anti-cancer pharmaceutical preparations; anti-fungal preparations; antiviral pharmaceutical preparations; bacteria removers, namely, antimicrobial preparations for inhibiting the growth of bacteria; biofilm removers, namely, antimicrobial preparations for inhibiting the growth of biofilms; biological preparations for the treatment of cancer and pseudomyxoma peritonei; chemical preparations containing enzymes for pharmaceutical purposes, namely, for the prevention and treatment of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD (chronic obstructive pulmonary disease), ARDS (acute respiratory distress syndrome), pneumonia, fungal infections and haemophilia; chemical preparations for pharmaceutical use, namely, for the prevention and treatment of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; compounds being pharmaceutical preparations for treating cancer; pharmaceutical compositions for the treatment and prevention of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; pharmaceutical preparations for the treatment and prevention of cancer and pseudomyxoma peritonei, for inhibiting the growth of bacteria or biofilms, for destroying biofilm infections, or for treating cystic fibrosis, sputum retention, chest infections, respiratory conditions, severe asthma, COPD, ARDS, pneumonia, fungal infections and haemophilia; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the prevention and treatment of pseudomyxoma peritonei; pharmaceutical preparations for use in combination therapy for the treatment of cancer and pseudomyxoma peritonei; pharmaceutical preparations for treating glue ear, cystic fibrosis, sputum retention, chest infections, respiratory conditions, haemophilia, myocardial infarction, coronary artery disease, stroke, massive pulmonary embolism, acute limb ischemia, stent-related thrombosis or haemarthrosis; preparations of plants, namely, plant extracts for pharmaceutical use

Trademark Events
Jan 3, 2023
Teas Change Of Correspondence Received
Jan 3, 2023
Teas Change Of Domestic Representatives Address
Jan 3, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 3, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 18, 2022
Registered-Principal Register
Nov 2, 2021
Official Gazette Publication Confirmation E-Mailed
Nov 2, 2021
Published For Opposition
Oct 13, 2021
Notification Of Notice Of Publication E-Mailed
Sep 28, 2021
Law Office Publication Review Completed
Sep 28, 2021
Approved For Pub - Principal Register
Sep 27, 2021
Teas/Email Correspondence Entered
Sep 27, 2021
Correspondence Received In Law Office
Sep 26, 2021
Assigned To Lie
Sep 20, 2021
Teas Response To Suspension Inquiry Received
Jul 29, 2021
Notification Of Letter Of Suspension E-Mailed
Jul 29, 2021
Letter Of Suspension E-Mailed
Jul 29, 2021
Suspension Letter Written
Jul 12, 2021
Teas/Email Correspondence Entered
Jul 12, 2021
Correspondence Received In Law Office
Jul 12, 2021
Teas Response To Office Action Received
Feb 3, 2021
Notification Of Non-Final Action E-Mailed
Feb 3, 2021
Non-Final Action E-Mailed
Feb 3, 2021
Non-Final Action Written
Feb 3, 2021
Assigned To Examiner
Oct 27, 2020
New Application Office Supplied Data Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24